Scancell Holdings PLC (SCLP)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

9.00p

Buy

9.50p

arrow-down-0.35p (-3.68%)

Scancell Holdings PLC is a biopharmaceutical company focused on the cancer therapeutics market. The company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer.
Prices updated at 13 May 2025, 14:34 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Sector
Healthcare
Industry
Biotechnology
Chairman
Ms. Susan Elizabeth Clement-Davies
CEO
Dr. Philip John L'Huillier
Most recent earnings
30 Apr 2024
Fiscal year end
30 Apr 2024
Employees
58
Head office
Sanders Road
Oxford
United Kingdom
OX4 4GD
mobile
+44 1865582066
letter
-

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Susan Elizabeth Clement-Davies
Non-Executive Director, Deputy Chairman
-----
Mr. Martin Henry Diggle
Non-Executive Director
-----
Mr. Sath Nirmalananthan
Executive Director, Chief Financial Officer
-----
Dr. Philip John L'Huillier
Executive Director, Chief Executive Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
AXA Investment Managers UK Ltd24,294,8560.58394--30 Apr 20252.61
UTM IM GBP AXA Framlington Biotech24,294,8560.58394--30 Apr 20252.61
Calculus Capital Limited2,531,0340.88624-25063-30 Apr 20250.27
Calculus VCT2,531,0340.88624-25063-0.98051830 Apr 20250.27
AXA Investment Managers Paris S.A.1,019,3150.614539531-30 Apr 20250.11

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
10 Dec 2024PurchaseMr. Sath Nirmalananthan10.5020,000190,4760.02Placing
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.